Trial · NCT00982423
The Effects of Decreasing the Lasix Dose on the Cardiorenal System
NCT00982423, Phase 1, Phase 2, Completed, Mayo Clinic; results first posted 2015-07-20
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. The Effects of Decreasing the Lasix Dose on the Cardiorenal System. Trials, record NCT00982423. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00982423
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Decreasing the Lasix Dose on the Cardiorenal System
- NCT number
- NCT00982423
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 41 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Heart Failure, Kidney Dysfunction
- Interventions
- Furosemide
- First posted
- 2009-09-23
- Last updated
- 2015-07-20
- Results first posted
- 2015-07-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | Kidney function was measured by GFR determined by iothalamate clearance. GFR describes the flow rate of filtered fluid through the kidney measured in milliliters per minute per 1.73 m\^2 of body surface area. A lower GFR means the kidney is not filtering normally. An estimated GFR of less than 60 mg/min/1.73 m\^2 of body surface area is considered to be impaired kidney function. |
| Secondary | Renal Plasma Flow at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | Effective renal plasma flow (eRPF) is a measure used to calculate renal plasma flow (RPF) and hence estimate renal function. Renal plasma flow is the volume of blood plasma that flows through the kidneys per unit time, measured as ml/min. |
| Secondary | Aldosterone at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | Aldosterone is part of the renin-angiotensin-aldosterone system (RAAS). Drugs that interfere with the secretion or action of aldosterone are in use as antihypertensives, like lisinopril, which lowers blood pressure by blocking the angiotensin-converting enzyme (ACE), leading to lower aldosterone secretion. The net effect of these drugs is to reduce sodium and water retention but increase retention of potassium. |
| Secondary | Plasma Renin Activity at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | Plasma renin activity is a measure of the activity of the plasma enzyme renin, which plays a major role in the body's regulation of blood pressure, thirst, and urine output. Renin is an enzyme that hydrolyses angiotensinogen secreted from the liver into the peptide angiotensin I. Renin's primary function is to cause an increase in blood pressure, leading to restoration of perfusion pressure in the kidneys. |
| Secondary | Angiotensin II at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | Renin activates the renin-angiotensin system by cleaving angiotensinogen, produced by the liver, to yield angiotensin I, which is further converted into angiotensin II by the angiotensin-converting enzyme (ACE) primarily within the capillaries of the lungs. Angiotensin II then constricts blood vessels, increases the secretion of antidiuretic hormone (ADH) and aldosterone, and stimulates the hypothalamus to activate the thirst reflex, each leading to an increase in blood pressure. |
| Secondary | Plasma Cyclic Guanosine Monophosphate (cGMP) at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | Any change in atrial filling pressures leads to the release of atrial natriuretic peptides (ANP) from the heart. Once released, atrial peptides exert potent direct vasodilator and natriuretic actions by virtue of the ability to increase their intracellular second messenger, cGMP. Plasma cGMP correlates closely with the severity of congestive heart failure. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | ml/min | MEAN | |
| SECONDARY | Renal Plasma Flow at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | ml/min | MEAN | |
| SECONDARY | Aldosterone at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | ng/dL | MEAN | |
| SECONDARY | Plasma Renin Activity at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | ng/mL/hr | MEAN | |
| SECONDARY | Angiotensin II at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | pg/mL | MEAN | |
| SECONDARY | Plasma Cyclic Guanosine Monophosphate (cGMP) at Baseline and in Response to Decreasing Furosemide Dose | 3 weeks, approximately 6 weeks | pg/mL | MEAN |
Source ClinicalTrials.gov
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF Without Renal Dysfunction | Baseline (3 weeks) | 77 | Standard Deviation 3 | ml/min |
| Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF With Renal Dysfunction | Baseline (3 weeks) | 42 | Standard Deviation 3 | ml/min |
| Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF Without Renal Dysfunction | Approximately 6 weeks | 73 | Standard Deviation 5 | ml/min |
| Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF With Renal Dysfunction | Approximately 6 weeks | 50 | Standard Deviation 4 | ml/min |
| Renal Plasma Flow at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF Without Renal Dysfunction | Baseline (3 weeks) | 304 | Standard Deviation 19 | ml/min |
| Renal Plasma Flow at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF With Renal Dysfunction | Baseline (3 weeks) | 198 | Standard Deviation 20 | ml/min |
| Renal Plasma Flow at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF Without Renal Dysfunction | Approximately 6 weeks | 293 | Standard Deviation 23 | ml/min |
| Renal Plasma Flow at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF With Renal Dysfunction | Approximately 6 weeks | 214 | Standard Deviation 21 | ml/min |
| Aldosterone at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF Without Renal Dysfunction | Baseline (3 weeks) | 7.9 | Standard Deviation 1.8 | ng/dL |
| Aldosterone at Baseline and in Response to Decreasing Furosemide Dose | Compensated CHF With Renal Dysfunction | Baseline (3 weeks) | 4.9 | Standard Deviation 0.6 | ng/dL |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Compensated CHF Without Renal Dysfunction | 13 | |
| Overall Study | STARTED | Compensated CHF With Renal Dysfunction | 19 | |
| Overall Study | COMPLETED | Compensated CHF Without Renal Dysfunction | 13 | |
| Overall Study | COMPLETED | Compensated CHF With Renal Dysfunction | 19 | |
| Overall Study | NOT COMPLETED | Compensated CHF Without Renal Dysfunction | 0 | |
| Overall Study | NOT COMPLETED | Compensated CHF With Renal Dysfunction | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dysuria | Renal and urinary disorders | Compensated CHF Without Renal Dysfunction | 0 | 13 | 0 |
| other | Dysuria | Renal and urinary disorders | Compensated CHF With Renal Dysfunction | 1 | 19 | 1 |
| serious | Hyperkalemia | Renal and urinary disorders | Compensated CHF Without Renal Dysfunction | 0 | 13 | 0 |
| serious | Hyperkalemia | Renal and urinary disorders | Compensated CHF With Renal Dysfunction | 1 | 19 | 1 |
| serious | Chest pain | Cardiac disorders | Compensated CHF Without Renal Dysfunction | 0 | 13 | 0 |
| serious | Chest pain | Cardiac disorders | Compensated CHF With Renal Dysfunction | 1 | 19 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Compensated CHF Without Renal Dysfunction | ||
| Total, all-cause mortality | Compensated CHF With Renal Dysfunction | ||
| Total, other adverse events | Compensated CHF Without Renal Dysfunction | 0 | 13 |
| Total, other adverse events | Compensated CHF With Renal Dysfunction | 1 | 19 |
| Total, serious adverse events | Compensated CHF Without Renal Dysfunction | 0 | 13 |
| Total, serious adverse events | Compensated CHF With Renal Dysfunction | 2 | 19 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25262369 | RESULT |
Source PubMed
Grants3
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R01HL084155 | Human Cardiorenal Syndrome | CHEN, HORNG H | MAYO CLINIC ROCHESTER | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2009 to 2025 | NIH RePORTER |
| P01HL076611 | Biology and Novel Therapeutics of Cardiovascular Peptides | BURNETT, JOHN C | MAYO CLINIC ROCHESTER | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2005 to 2015 | NIH RePORTER |
| UL1TR000135 | Mayo Clinic Center for Clinical and Translational Science (CCaTS) | KHOSLA, SUNDEEP | MAYO CLINIC ROCHESTER | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2012 to 2015 | NIH RePORTER |
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Compensated CHF Without Renal Dysfunction vs Compensated CHF With Renal Dysfunction: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00982423
GET https://conductscience.org/api/trials/v1/NCT00982423/results?page=2